Novel metabolomics-biohumoral biomarkers model for predicting survival of metastatic soft-tissue sarcomas.
Cancer
Metabolomics
Systems biology
Journal
iScience
ISSN: 2589-0042
Titre abrégé: iScience
Pays: United States
ID NLM: 101724038
Informations de publication
Date de publication:
20 Oct 2023
20 Oct 2023
Historique:
received:
22
03
2023
revised:
23
06
2023
accepted:
14
08
2023
medline:
27
9
2023
pubmed:
27
9
2023
entrez:
27
9
2023
Statut:
epublish
Résumé
Soft tissue sarcomas (STSs) are rare malignant tumors that are difficult to prognosticate using currently available instruments. Omics sciences could provide more accurate and individualized survival predictions for patients with metastatic STS. In this pilot, hypothesis-generating study, we integrated clinicopathological variables with proton nuclear magnetic resonance (
Identifiants
pubmed: 37752948
doi: 10.1016/j.isci.2023.107678
pii: S2589-0042(23)01755-8
pmc: PMC10518687
doi:
Types de publication
Journal Article
Langues
eng
Pagination
107678Informations de copyright
© 2023.
Déclaration de conflit d'intérêts
The authors declare no competing interests.
Références
Philos Trans A Math Phys Eng Sci. 2009 Nov 13;367(1906):4255-71
pubmed: 19805444
Cell. 2018 Oct 4;175(2):502-513.e13
pubmed: 30245009
Cancer Res. 2012 Jan 1;72(1):356-64
pubmed: 22080567
Nat Rev Cancer. 2016 Nov;16(11):708-717
pubmed: 27562461
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
PLoS One. 2015 Feb 17;10(2):e0116515
pubmed: 25689462
NPJ Breast Cancer. 2019 Aug 29;5:26
pubmed: 31482106
BMC Bioinformatics. 2014;15 Suppl 16:S11
pubmed: 25521394
Cancers (Basel). 2021 Nov 21;13(22):
pubmed: 34830999
Cancer Med. 2016 Dec;5(12):3437-3444
pubmed: 27882721
Br J Cancer. 2001 Apr 20;84(8):1070-5
pubmed: 11308256
Int J Mol Sci. 2021 Apr 28;22(9):
pubmed: 33925233
Transl Oncol. 2021 Jun;14(6):101043
pubmed: 33751965
Sci Rep. 2019 Jul 16;9(1):10319
pubmed: 31311965
Drug Resist Updat. 2015 Mar;19:33-42
pubmed: 25575621
Nat Rev Cancer. 2016 Nov;16(11):732-749
pubmed: 27658529
Cancers (Basel). 2020 Jan 29;12(2):
pubmed: 32013102
Cancer Res. 2016 Apr 15;76(8):2063-70
pubmed: 27197250
Discov Oncol. 2022 Jul 7;13(1):58
pubmed: 35798917
Mol Cell. 2017 Jun 1;66(5):684-697.e9
pubmed: 28552616
Int J Mol Sci. 2022 Jun 29;23(13):
pubmed: 35806209
Curr Protoc Pharmacol. 2017 Mar 17;76:9.23.1-9.23.17
pubmed: 28306150
Lancet Oncol. 2016 May;17(5):671-80
pubmed: 27068860
Br J Cancer. 2019 Jun;120(12):1090-1098
pubmed: 31092908
Cell. 2014 Dec 18;159(7):1591-602
pubmed: 25525877
Elife. 2022 Sep 02;11:
pubmed: 36052997
PLoS One. 2014 Sep 10;9(9):e107297
pubmed: 25207808
Medicine (Baltimore). 2020 May 22;99(21):e20165
pubmed: 32481285
Cancer Cell. 2015 Jan 12;27(1):57-71
pubmed: 25584894
Bioinformatics. 2012 Jan 1;28(1):112-8
pubmed: 22039212
BMC Med. 2019 Jan 7;17(1):3
pubmed: 30616610
Anal Chem. 2018 Oct 16;90(20):11962-11971
pubmed: 30211542
Cancer Cell Int. 2021 Jan 20;21(1):62
pubmed: 33472628
Cancers (Basel). 2022 Jun 12;14(12):
pubmed: 35740562
Cancer Sci. 2009 May;100(5):821-7
pubmed: 19445015
Oncogene. 2019 Oct;38(44):6970-6984
pubmed: 31409901
Angew Chem Int Ed Engl. 2019 Jan 21;58(4):968-994
pubmed: 29999221
Endocrinol Metab Clin North Am. 2022 Sep;51(3):437-458
pubmed: 35963623
Am J Cancer Res. 2019 Feb 01;9(2):219-227
pubmed: 30906624
Cancers (Basel). 2020 Jul 21;12(7):
pubmed: 32708128
EClinicalMedicine. 2019 Nov 22;17:100215
pubmed: 31891146
Int J Gynecol Cancer. 2020 Oct;30(10):1520-1527
pubmed: 32839227
Cancer Res. 1996 Mar 1;56(5):941-3
pubmed: 8640781
Medicine (Baltimore). 2021 Sep 17;100(37):e27221
pubmed: 34664860
Anal Chem. 2015 Jul 7;87(13):6709-17
pubmed: 26020452
Nat Rev Clin Oncol. 2011 Aug 09;8(12):711-9
pubmed: 21826083
Cell. 2014 Dec 18;159(7):1492-4
pubmed: 25525870
Cancer. 2017 Aug 1;123(15):2802-2820
pubmed: 28493287
Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):13892-7
pubmed: 26504198
Ann Oncol. 2021 Sep;32(9):1178-1187
pubmed: 34139273
Science. 1986 Apr 4;232(4746):34-47
pubmed: 3513311
Nat Commun. 2016 Jun 30;7:11960
pubmed: 27357947